US incentive scheme for neglected diseases: a good idea gone wrong?
| dc.contributor.author | Doshi, Peter | |
| dc.date.accessioned | 2017-05-25T01:16:02Z | |
| dc.date.available | 2017-05-25T01:16:02Z | |
| dc.date.issued | 2014-07-21 | |
| dc.identifier.citation | Doshi, P. (2014). US incentive scheme for neglected diseases: a good idea gone wrong? BMJ, 349. DOI: 10.1136/bmj.g4665 | |
| dc.identifier.uri | http://hdl.handle.net/10713/6607 | |
| dc.description | The US priority review voucher scheme was intended to encourage drug companies to invest in treatments for neglected diseases. But nearly seven years on, the author reports, there is little demonstrated innovation and evidence that the benefits are not going where they were intended. | |
| dc.description.uri | http://bmj.com/cgi/content/full/bmj.g4665?ijkey=BfocpzBr7dwheEA&keytype=ref | |
| dc.language.iso | en_US | en_US |
| dc.publisher | BMJ Publishing Group | en_US |
| dc.subject | Knight Therapeutics | en_US |
| dc.subject | miltefosine | en_US |
| dc.subject | priority review vouchers | en_US |
| dc.subject.lcsh | United States. Food and Drug Administration | en_US |
| dc.subject.mesh | Drug Approval--economics | en_US |
| dc.subject.mesh | Neglected Diseases--drug therapy | en_US |
| dc.title | US incentive scheme for neglected diseases: a good idea gone wrong? | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1136/bmj.g4665 | |
| dc.identifier.pmid | 25099712 | |
| dc.identifier.ispublished | No | en_US |
| dc.description.uriname | Click here for the free full-text article on publisher’s website | en_US |
| refterms.dateFOA | 2019-02-19T18:15:37Z |
